Myriad Genetics (MYGN) Statistics

Gene therapy and molecular diagnostics company Myriad Genetics Inc (MYGN) has attracted attention from investors and analysts alike, thanks to its impressive stock statistics. With a market capitalization of over $1 billion, MYGN is a significant player in the healthcare sector. When it comes to valuation metrics, MYGN stands out with a price-to-earnings ratio (P/E) of 20. This suggests that investors are willing to pay 20 times the company's earnings for each share. Additionally, the price-to-sales ratio (P/S) is 3, indicating that MYGN's revenue per share is favorable.

A closer look at MYGN's fundamentals reveals a strong performance in comparison to its sector. The company has consistently outperformed its peers, showcasing its resilience and innovation. MYGN's revenue per share is impressive, demonstrating consistent growth in its top line. Furthermore, the Enterprise to EBITDA ratio indicates that MYGN is effectively managing its debt, which is essential for long-term success. The profit margin of MYGN is also worth noting, as it demonstrates the company's ability to generate profit from each dollar of sales. Lastly, MYGN has managed its total debt prudently, allowing room for future investments.